Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Healthcare

EMvision Medical Devices Ltd (ASX:EMV): Stroke Scanner Trials and Portable Brain Imaging Progress

EMvision Medical Devices Ltd (ASX:EMV) develops portable, non-invasive neurodiagnostic technology aimed at bringing brain imaging closer to patients. Its work focuses on the emu bedside brain scanner and a separate first responder concept. During 2026, the company has reported further hospital participation in the …

Aditi Sarkar | 12 October 2026

Entropy Neurodynamics Limited (ASX:ENP): Clinical Updates Across Its Psilocin Programs

The company’s TRP-8803 formulation delivers psilocin intravenously, with dosing intended to be controlled during a supervised treatment session. Entropy Neurodynamics (ASX:ENP) has pursued clinical work examining this approach for binge eating disorder (BED), a condition involving recurrent episodes of uncontrolled eating. A January 2026 …

Aditi Sarkar | 12 October 2026

Epsilon Healthcare Limited (ASX:EPN): Manufacturing and Pharmacy Operations Develop in 2026

For the three months ended 30 June 2026, Epsilon Healthcare (ASX:EPN) reported customer receipts of $3.66 million, an increase of 72% against the corresponding quarter. The company reported group revenue of $4.7 million for the quarter, compared with $3.3 million in the March 2026 …

Aditi Sarkar | 12 October 2026

CurveBeam AI Limited (ASX:CVB): Orthopaedic CT Imaging and Bone Health Technology

The HiRise system captures three-dimensional images of the lower extremities, including examinations conducted while patients bear weight. That capability gives clinicians a view of bone and joint alignment under load, which can differ from non-weight-bearing assessment. CurveBeam AI (ASX:CVB) also offers equipment for extremity …

Aditi Sarkar | 12 October 2026

Cyclopharm Limited (ASX:CYC): Technegas US Expansion and First-Half 2026 Results

For the six months ended 30 June 2026, Cyclopharm Limited (ASX:CYC) reported total revenue of $17.5m, representing a 14% increase on the prior corresponding period. The group reported a gross margin of 56.3%, compared with 53.5% a year earlier. Its net loss after tax …

Aditi Sarkar | 12 October 2026

Cynata Therapeutics Limited (ASX:CYP): Clinical Trial Results Shape Regenerative Medicine Priorities

Cynata Therapeutics (ASX:CYP) uses its Cymerus platform to produce MSCs from induced pluripotent stem cells. The manufacturing approach is intended to support the production of allogeneic, or donor-independent, cell therapy products. It does not, by itself, establish clinical efficacy or regulatory approval. The products …

Aditi Sarkar | 12 October 2026

Ceryvyn Therapeutics Limited (ASX:CYV): CYV-101 Development for Rare Lung Disease

Ceryvyn Therapeutics Limited (ASX:CYV) is an Australian biotechnology company developing a biologic treatment for lymphangioleiomyomatosis (LAM), a rare disease that progressively affects lung function. Its lead candidate, CYV-101, is intended to intervene in biological pathways associated with abnormal lymphatic activity. During 2026, the company …

Aditi Sarkar | 12 October 2026

EVE Health Group Limited (ASX:EVE): Pharmaceutical Reformulation and Australian Product Rollout

In February 2026, EVE Health Group (ASX:EVE) announced the Australian launch of Libbo, an oral dissolving film developed for the treatment of erectile dysfunction. The rollout was accompanied by a digital pathway intended to connect patient information, clinical assessment, prescriptions and delivery. This arrangement …

Aditi Sarkar | 12 October 2026

Nova Eye Medical (ASX:EYE): iTrack Advance and the Expansion of Glaucoma Care

The iTrack Advance system is designed for canaloplasty, a procedure that accesses and dilates the eye’s conventional drainage pathway to help reduce intraocular pressure in patients with open-angle glaucoma. The device uses an illuminated microcatheter and viscodilation technique. Nova Eye Medical (ASX:EYE) markets the …

Aditi Sarkar | 12 October 2026

EBR Systems, Inc. (ASX:EBR): WiSE Cardiac Pacing Commercialisation and 2026 Manufacturing Progress

The WiSE System uses an implanted electrode within the left ventricle and an ultrasound-based transmitter to deliver precisely timed electrical stimulation. It is intended for eligible patients who cannot receive or have not responded adequately to conventional CRT approaches. The system is a medical …

Aditi Sarkar | 12 October 2026
Support

Hi! How can we help you today?

Loading…